CTSO - Cytosorbents Corporation

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
7.70
+0.25 (+3.36%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close7.45
Open7.50
Bid6.25 x 2400
Ask7.90 x 700
Day's Range7.30 - 7.75
52 Week Range3.30 - 7.90
Volume82,903
Avg. Volume132,962
Market Cap220.923M
Beta1.69
PE Ratio (TTM)N/A
EPS (TTM)-0.40
Earnings DateMar 1, 2018 - Mar 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.06
Trade prices are not sourced from all markets
  • Zacks Small Cap Research8 days ago

    CTSO: Q4 Preannouncement, Our Initial Thoughts on REFRESH II

    Clearly uptake and adoption of CytSorb is growing, as evidenced by not only the rapid product sales growth but also by the number of procedures during which the device has been employed.  As of the end of 2017, more than 35k CytoSorb treatments were delivered – up from about 20k (i.e. While we think the potential for qoq volatility in product sales remains, we also continue to believe product sales will trend higher given several catalysts which we have discussed in prior updates.  These include the improved reimbursement picture in Germany, continued robust product sales growth from existing distributors OG (i.e.

  • GlobeNewswire11 days ago

    New Research: Key Drivers of Growth for Merit Medical, NETGEAR, Hancock Holding, Alexandria Real Estate Equities, Cytosorbents, and Stepan — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Jan. 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Merit ...

  • PR Newswire12 days ago

    CytoSorbents Pre-Announces Preliminary Fourth Quarter and Full Year 2017 Results and Issues Stockholder Letter

    MONMOUTH JUNCTION, N.J., Jan. 8, 2018 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, pre-announces preliminary unaudited fourth quarter 2017 and full year 2017 results ahead of filing its Form 10-K, and issues a stockholder letter from Dr. Phillip Chan, Chief Executive Officer of CytoSorbents.

  • PR Newswire17 days ago

    CytoSorbents To Provide Corporate Update at Biotech Showcase 2018

    MONMOUTH JUNCTION, N.J. , Jan. 3, 2018 /PRNewswire/ --  CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly ...

  • CytoSorbents Corp. :CTSO-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018
    Capital Cube19 days ago

    CytoSorbents Corp. :CTSO-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018

    Categories: Yahoo FinanceGet free summary analysis CytoSorbents Corp. reports financial results for the quarter ended September 30, 2017. Highlights Summary numbers: Revenues of USD 3.82 million, Net Earnings of USD -2.05 million. Gross margins widened from 60.03% to 60.34% compared to the same period last year, operating (EBITDA) margins now -54.67% from -87.25%. Change in operating cash ... Read more (Read more...)

  • GlobeNewswire23 days ago

    Streetwise Reports Examines an Immunotherapy Firm That Received a Green Light from FDA for Pivotal Trial

    SAN FRANCISCO, Dec. 28, 2017-- Jason Kolbert, an analyst with Maxim Group, described the study, which enables this biotech's device to be used in patients undergoing heart surgery and will measure its ...

  • PR Newswirelast month

    CytoSorbents Achieves Key Milestone with FDA Approval of the U.S. REFRESH 2 Pivotal Cardiac Surgery Trial IDE Application

    MONMOUTH JUNCTION, N.J., Dec. 21, 2017 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that the U.S. Food and Drug Administration (FDA) has granted approval of its REFRESH 2 Investigational Device Exemption (IDE) application, with conditions.  These conditions relate to requested clarifications and changes to the patient consent form and Instructions for Use document, which have now been modified.  Based on FDA guidance, study initiation and patient enrollment can now begin at each clinical center with site institutional review board (IRB) approval and the revised documentation. Dr. Eric Mortensen, Chief Medical Officer of CytoSorbents stated, "The FDA approval of our REFRESH 2 trial IDE application is a major milestone for our clinical program.

  • Zacks Small Cap Researchlast month

    CTSO: Large Infective Endocarditis Clinical Study Could Be Win-Win for CytoSorbents

    By Brian Marckx, CFA NASDAQ:CTSO Large, Randomized Clinical Study Aims to Further Validate CytoSorb Efficacy in Infective Endocarditis..  As a reminder, a manuscript of a retrospective case series involving ...

  • PR Newswirelast month

    CytoSorbents Receives $676,739 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program

    MONMOUTH JUNCTION, N.J. , Dec. 19, 2017 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO ), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly ...

  • PR Newswirelast month

    German Federal Ministry of Education and Research to Fund the CytoSorb® Endocarditis REMOVE Trial

    MONMOUTH JUNCTION, N.J., Dec. 11, 2017 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader using CytoSorb® blood purification to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that the German Federal Ministry of Education and Research will fund the largest randomized controlled trial using CytoSorb in infective endocarditis patients to date.

  • Capital Cubelast month

    ETFs with exposure to CytoSorbents Corp. : December 8, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CytoSorbents Corp. Here are 5 ETFs with the largest exposure to CTSO-US. Comparing the performance and risk of CytoSorbents Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • PR Newswire2 months ago

    CytoSorbents to Present at the LD Micro Main Event Investor Conference

    MONMOUTH JUNCTION, N.J. , Nov. 29, 2017 /PRNewswire/ --  CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using blood purification to prevent or treat life-threatening injury ...

  • Is Cytosorbents Corporation’s (CTSO) Balance Sheet Strong Enough To Weather A Storm?
    Simply Wall St.2 months ago

    Is Cytosorbents Corporation’s (CTSO) Balance Sheet Strong Enough To Weather A Storm?

    Investors are always looking for growth in small-cap stocks like Cytosorbents Corporation (NASDAQ:CTSO), with a market cap of USD $195.10M. However, an important fact which most ignore is: how financiallyRead More...

  • Zacks Small Cap Research2 months ago

    CTSO: Germany Reimbursement Rebounds, Drives Strong Record Product

    CytoSorbents (CTSO) reported financial results for their third quarter ending September 30th and provided a business update.  Product sales returned to growth – on both a yoy and sequential basis and set a new record high, eclipsing the previous best (Q2 2017) by 13% and beating our estimate by a healthy 10%.  The recent inflection in product sales is encouraging given that they edged down from Q4 ’16 to Q1 ’17 – which was attributed to a change in reimbursement in Germany.  At that time, management indicated that they expected the issue would dissipate with availability of the new (i.e. Indications, including results of a survey (about reimbursement) of some of CTSO's key German accounts as well as an increase in rates by as much as 100% in some locations, suggest that is what has happened.  Certainly, the sequential revenue growth also supports that same theme - product revenue grew 17% from Q1 to Q2 and another 13% from Q2 to Q3.

  • Associated Press2 months ago

    CytoSorbents reports 3Q loss

    On a per-share basis, the Monmouth Junction, New Jersey-based company said it had a loss of 7 cents. The results met Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • PR Newswire2 months ago

    CytoSorbents Continues Strong Trajectory of Growth in the Third Quarter 2017

    Company achieved record quarterly total sales of $3.8 million , and record quarterly and trailing twelve-month product sales of $3.4 million and $11.7 million , respectively MONMOUTH JUNCTION, N.J. , Nov. ...

  • ACCESSWIRE2 months ago

    CytoSorbents Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 9, 2017 / CytoSorbents Corporation (NASDAQ: CTSO ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 9, 2017 at 4:45 PM Eastern ...

  • Capital Cube2 months ago

    ETFs with exposure to CytoSorbents Corp. : November 9, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CytoSorbents Corp. Here are 5 ETFs with the largest exposure to CTSO-US. Comparing the performance and risk of CytoSorbents Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • PR Newswire2 months ago

    CytoSorbents Recognized on Deloitte's 2017 Technology Fast 500™ as One of the Fastest Growing Companies in North America

    MONMOUTH JUNCTION, N.J., Nov. 9, 2017 /PRNewswire/ -- CytoSorbents Corporation (CTSO) announced that at last evening's awards ceremony, it ranked 7th amongst 21 medical device companies, and 297th overall in any industry on Deloitte's 2017 Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, healthcare and life sciences, and energy tech companies in North America.  The company's revenues grew by 293% in the three-year period from 2013 to 2016.

  • Capital Cube3 months ago

    ETFs with exposure to CytoSorbents Corp. : October 30, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CytoSorbents Corp. Here are 5 ETFs with the largest exposure to CTSO-US. Comparing the performance and risk of CytoSorbents Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Zacks Small Cap Research3 months ago

    CTSO: Additional Evidence Supporting CytoSorb Use in Sepsis, Cardiac Surgery

    CytoSorbents (CTSO) recently announced the publication of two unrelated studies (one in sepsis, the other in cardiac surgery), data from both of which provided additional evidence of CytoSorb’s utility in, and relationship with, removing cytokines and other inflammatory mediators from circulation and improved patient outcomes.

  • Capital Cube3 months ago

    ETFs with exposure to CytoSorbents Corp. : October 20, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CytoSorbents Corp. Here are 5 ETFs with the largest exposure to CTSO-US. Comparing the performance and risk of CytoSorbents Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • PR Newswire3 months ago

    CytoSorbents to Present at the 2017 BIO Investor Forum

    MONMOUTH JUNCTION, N.J. , Oct. 10, 2017 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using CytoSorb® blood purification to treat deadly inflammation in ...

  • CytoSorbents Corp. :CTSO-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
    Capital Cube3 months ago

    CytoSorbents Corp. :CTSO-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017

    Categories: Yahoo FinanceGet free summary analysis CytoSorbents Corp. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 3.57 million, Net Earnings of USD -1.12 million. Gross margins narrowed from 60.71% to 58.44% compared to the same period last year, operating (EBITDA) margins now -64.23% from -119.26%. Change in operating cash ... Read more (Read more...)

  • PR Newswire4 months ago

    CytoSorbents Introduces the CytoSorb Therapeutic ECMO™ Kit at the 2017 European Society of Intensive Care Medicine Congress

    Enables a new powerful combined therapy to treat respiratory failure and shock MONMOUTH JUNCTION, N.J. , Sept. 26, 2017 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy ...